Skip to main content

Advertisement

Table 1 Demographics and characteristics of study patients by baseline CD4 strata and HIV type

From: Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire

 Baseline CD4 < 200 cells/μlBaseline CD4 200–500 cells/μl 
HIV-1HIV-2HIV-DTotalHIV-1HIV-2HIV-DTotal
Total patients, n21657710823501049315711373487
Visits, median (IQR)7.0 (3–19)7.0 (3–16)7.0 (3–17)7.0 (3–19)8.0 (3–18)11.0 (3–21)7.5 (3–18.5)8.0 (3–18)7.0 (3–19)
Follow-up time (years), median (IQR)3.8 (0.7–11.2)3.0 (0.8–8.0)2.5 (0.7–10.7)3.7 (0.7–11.2)4.5 (1.0–11.3)5.6 (2.6–10.6)4.7 (1.4–11.0)4.6 (1.0–11.3)4.0 (0.8–11.2)
Year of baseline CD4, n (%)
 1998–2000444 (20.5)15 (19.5)29 (26.9)488 (20.8)254 (24.2)8 (25.8)11 (19.3)273 (24.0)761 (21.8)
 2001–2002768 (35.5)31 (40.3)40 (37.0)839 (35.7)394 (37.6)10 (32.3)27 (47.4)431 (37.9)1270 (36.4)
 2003–2004953 (44.0)31 (40.3)39 (36.1)1023 (43.5)401 (38.2)13 (41.9)19 (33.3)433 (38.1)1456 (41.8)
CD4 count (cells/μl), median (IQR)69 (21–127)69 (42–112)71 (23–125)69 (22–126)299 (246–381)282 (236–373)312 (250–382)299 (246–381)128 (41–244)
Age (years)
 Age, mean ± SD37.8 ± 8.743.8 ± 8.341.4 ± 6.638.2 ± 8.736.7 ± 9.441.3 ± 9.339.7 ± 8.337.0 ± 9.437.8 ± 9.0
 < 35, n (%)837 (38.7)8 (10.4)15 (13.9)860 (36.6)487 (46.4)6 (19.4)17 (29.8)510 (44.9)1370 (39.3)
 35–44, n (%)844 (39.0)39 (50.6)57 (52.8)940 (40.0)358 (34.1)11 (35.5)28 (49.1)397 (34.9)1337 (38.3)
 ≥ 45, n (%)484 (22.4)30 (39.0)36 (33.3)550 (23.4)204 (19.4)14 (45.2)12 (21.1)230 (20.2)780 (22.4)
Sex, n (%)
 Female1107 (51.1)33 (42.9)37 (34.3)1177 (50.1)626 (59.7)11 (35.5)29 (50.9)666 (58.6)1843 (52.9)
 Male1058 (48.9)44 (57.1)71 (65.7)1173 (49.9)423 (40.3)20 (64.5)28 (49.1)471 (41.4)1644 (47.2)
Percentage of visits with documented ART regimen, n (%)
 < 50%216 (10.0)8 (10.4)12 (11.1)236 (10.0)307 (29.2)8 (25.8)15 (26.3)330 (29.0)566 (16.2)
 50–75%614 (28.3)26 (33.7)31 (28.7)671 (28.6)229 (21.8)6 (19.4)17 (29.8)252 (22.2)923 (26.5)
 > 75%1335 (61.7)43 (55.8)65 (60.1)1443 (61.4)513 (48.9)17 (54.8)25 (43.8)555 (48.8)1998 (57.3)
  1. Values are reported as median (IQR), mean ± SD, or n(%). Visits and follow-up time refer only to visits recorded in the RETRO-CI laboratory database – if visits did not include specimen referrals to RETRO-CI they were not included. The percentage of visits with a documented ART regimen refers to visits in the RETRO-CI database (not including the initial visit) for which a current ART regimen was recorded
  2. Abbreviations: IQR Interquartile range, SD Standard deviation, ART Antiretroviral therapy